Aviado · Research
Longevity Daily
Saturday, May 9, 2026
Listen
Today's Brief
Today's digest leads with a National Geographic investigation into Alzheimer's warning signs that surface before amyloid plaques appear — signals most people are missing. Peter Attia weighs in on menopause as a genuine neurological turning point, backed by brain imaging data. A landmark Nature Metabolism study cracks metformin's long-debated mechanism: it works through the gut, not systemically as long assumed. Our Aviado analysis spotlights PLP — the active form of vitamin B6 — as one of the most revealing, and most overlooked, biomarkers in longevity medicine.
10 stories3 peer-reviewed1 Aviado original
Cognitive Health & Neuroprotection
The Early Alzheimer's Warning Signs That Appear Before Amyloid Plaques
Scientists are zeroing in on subtle changes in sleep, smell, vision, and spatial patterns that may signal Alzheimer's risk years before plaques show up on brain scans — meaning the intervention window is wider than most people realize. These pre-amyloid signals matter because earlier detection means more time to act, whether through lifestyle modification, monitoring, or emerging therapies. With an estimated 6 million Americans currently living with dementia and twice that number projected as the population ages, identifying these less visible changes has become a research priority. If you or someone close to you notices unexplained shifts in smell, sleep architecture, or spatial awareness, it's worth raising with a physician sooner rather than later.
Read more →Menopause Is a Neurological Event, Not Just a Reproductive One
Brain imaging data reveal that the perimenopausal transition triggers measurable changes in brain metabolism, glucose uptake, and even brain volume — making menopause a genuine neurological milestone, not just a hormonal one. Peter Attia breaks down why this transition period is a critical window for intervention and why timing matters far more than most physicians acknowledge. For women in their 40s and early 50s, this is a strong case for treating brain health as a first-order priority during the hormonal transition, not an afterthought.
Read more →GLP-1 Drugs Show Neuroprotective Promise Against Parkinson's Disease
Emerging research suggests GLP-1 receptor agonists — the drug class behind semaglutide and tirzepatide — may slow Parkinson's disease progression through anti-inflammatory and neuroprotective effects in the brain, acting on GLP-1 receptors present in dopaminergic neurons. The drugs appear to reduce the neuroinflammation that accelerates neuronal loss, adding a potential brain-health dimension to a class already reshaping metabolic medicine. Early clinical signals are promising, but larger dedicated Parkinson's trials are needed before this becomes standard guidance.
Read more →Supplements & Compounds
Your PLP Level Is a Hidden Report Card on Inflammation and Cancer Risk
Most people assume low vitamin B6 means they need to eat more B6-rich foods — but new research reveals that inflammation itself rapidly burns through PLP, the active form of B6, meaning low PLP often signals hidden inflammatory burden rather than poor diet. A study of nearly 2 million people found those with the highest PLP levels had 34% lower overall cancer risk and 46% lower colorectal cancer risk. The practical takeaway: test your plasma PLP, aim for levels above 50 nmol/L, and if you're deficient, supplement with pyridoxal-5'-phosphate (not standard B6) — and if levels stay low despite supplementation, investigate the upstream inflammation source.
Read the full Aviado analysis →Spearmint Extract Improves Sustained Attention Over 90 Days in Clinical Study
A clinical study of Neumentix — a proprietary spearmint extract concentrated in rosmarinic acid — found significant improvements in sustained attention beginning at 30 days that persisted through the full 90-day trial, suggesting long-term supplementation is key to realizing cognitive benefits from this botanical. Unlike most nootropic studies that only measure acute effects, the duration-based design here provides a more meaningful real-world signal. Independent replication is still needed, but this is one of the more rigorously designed botanical cognitive studies published recently.
Read more →Aged Garlic Compound S1PC Fights Frailty by Signaling from Fat Tissue to the Brain
Research published in Cell Metabolism identifies S-1-propenyl-L-cysteine (S1PC) — a metabolite found only in aged garlic extract, not raw garlic — as a potential anti-frailty compound that works by triggering a precise signaling cascade from fat tissue to the brain, boosting muscle strength and reducing frailty markers. The mechanism is notably specific and distinct from generic garlic supplements, making formulation matter. This is primarily preclinical mouse work, so human translation remains to be confirmed, but the Cell Metabolism platform and mechanistic specificity make it worth watching.
Read more →Research & Papers
How Metformin Really Works: The Gut, Not the Liver, Is the Key
A landmark Nature Metabolism study from Northwestern University overturns the long-held assumption that metformin lowers blood sugar primarily through the liver. Instead, the drug inhibits mitochondrial energy production in intestinal epithelial cells, forcing the gut to act as a glucose sink — absorbing and converting excess sugar before it reaches systemic circulation. For the longevity community already using metformin off-label, this doesn't change dosing, but it does reframe side effects, explains why bolus dosing matters more than chronic exposure, and opens new doors for gut-targeted metabolic drug design.
Read more →Lifestyle & Nutrition
Older Adults Are Using Edible Cannabis for Sleep and Pain — Mostly Without Medical Guidance
New research shows seniors are increasingly turning to edible cannabis — particularly THC/CBD combination products — to manage chronic pain and sleep disturbances, with most selecting doses based on peer advice rather than physician guidance. Researchers describe a "Goldilocks" self-titration pattern, where older adults seek formulations that provide relief without intense psychoactive effects. The findings highlight a real gap in clinical guidance for cannabis in aging populations, where altered drug metabolism and common polypharmacy make self-dosing meaningfully riskier than in younger adults.
Read more →Aging Guts Create the Perfect Environment for Harmful Bacteria
Research published in Aging Cell reveals how intestinal aging drives structural and immune changes — including degraded mucus layers and impaired local immune surveillance — that favor pathogenic bacteria while suppressing beneficial microbial populations, creating a self-reinforcing cycle of dysbiosis and systemic inflammation. The implication is that gut health interventions need to intensify with age, not stay static: the probiotic or prebiotic strategy that works at 40 may be functionally insufficient by 65. Supporting gut barrier integrity becomes a more urgent longevity target the older you get.
Read more →Industry & Policy
Congress Is Debating Whether Supplement Makers Must Register Products with the FDA
The House Dietary Supplement Listing Act would require manufacturers to register their products with the FDA for the first time — a significant regulatory shift for an industry that has operated largely on self-regulation since 1994. Supporters argue mandatory registration would improve transparency and safety for the 75%+ of Americans who take supplements; industry groups are pushing back on compliance burden. Anyone who relies on supplements should follow this closely: if passed, it could reshape what products remain on shelves, what label claims are permitted, and how safety issues are tracked.
Read more →